![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/10777492/47002105ovaleap300ie-0-5ml*750xx640-360-0-60.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA](https://www.fda.gov/files/styles/recall_image_small/public/7_1.jpg?itok=YhMegWXb)
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA
![Teva Pharmaceuticals - Next generation supply chain transformation by digitalisation at Teva by iThink Media - Issuu Teva Pharmaceuticals - Next generation supply chain transformation by digitalisation at Teva by iThink Media - Issuu](https://image.isu.pub/230602090740-8a821ba050264badd6cad5be3d343ca7/jpg/page_1_thumb_large.jpg)
Teva Pharmaceuticals - Next generation supply chain transformation by digitalisation at Teva by iThink Media - Issuu
![Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions](https://s40123.pcdn.co/wp-content/uploads/2022/03/recallTeva-700x547.jpg)
Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination - Top Class Actions
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg?download=1)